Biocryst Pharmaceuticals, Inc.
A biopharmaceutical company that develops medicines for rare diseases, BioCryst's flagship product is Orladeyo, an oral once-daily pill that prevents attacks of hereditary angioedema, a rare genetic condition causing sudden, painful swelling. Founded in 1986 in Birmingham, Alabama, the name blends "bio" with "cryst," a nod to the X-ray crystallography technique its scientists use to design drugs at the molecular level. The company also markets RAPIVAB, an antiviral treatment for influenza.
Granted 811.9K · Bought 30.0K
Granted 705.2K · Bought 30.0K
Granted 609.9K · Bought 5.0K · Sold 417.2K
Granted 154.7K · Bought 36.3K
Granted 176.9K · Bought 30.0K
Granted 268.7K
Granted 205.2K
Granted 44.2K · Bought 15.0K
Granted 19.3K · Bought 5.0K · Sold 7.0K
Granted 34.6K · Bought 21.9K
Granted 158.2K · Sold 126.6K
Granted 34.6K · Bought 7.9K
Granted 6.8K · Bought 2.5K
Granted 37.3K · Sold 19.8K
Granted 34.6K · Sold 14.3K
Granted 6.8K
Granted 35.5K
Granted 31.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Stonehouse Jon PDirector · 23 transactions | +56% | 2.84M | 811.9K | 30.0K | — |
| Gayer Charles KPresident and CCO · 13 transactions | +267.5% | 902.6K | 705.2K | 30.0K | — |
| Barnes Alane PChief Legal Officer · 20 transactions | +99% | 463.2K | 609.9K | 5.0K | 417.2K |
| Doyle AnthonyChief Financial Officer · 7 transactions | +90.9% | 377.9Kas of Dec 2024 | 154.7K | 36.3K | — |
| Thackray Helen M.Chief R&D Officer · 9 transactions | +82% | 377.3Kas of Mar 2025 | 176.9K | 30.0K | — |
| Ghias BabarChief Financial Officer · 2 transactions | — | 268.7K | 268.7K | — | — |
| Menon SandeepChief R&D Officer · 1 transaction | — | 205.2K | 205.2K | — | — |
| Milano VincentDirector · 16 transactions | +120.3% | 108.5K | 44.2K | 15.0K | — |
| Hutson Nancy JDirector · 4 transactions | +21.2% | 99.1Kas of Jun 2025 | 19.3K | 5.0K | 7.0K |
| Galson Steven KDirector · 4 transactions | — | 86.2K | 34.6K | 21.9K | — |
| Heggie TheresaDirector · 13 transactions | +64.2% | 80.6K | 158.2K | — | 126.6K |
| Levin Alan GDirector · 4 transactions | +114.5% | 79.6K | 34.6K | 7.9K | — |
| Aselage SteveDirector · 2 transactions | — | 72.7Kas of Jun 2024 | 6.8K | 2.5K | — |
| McKee Amy EDirector · 9 transactions | +59.3% | 47.2K | 37.3K | — | 19.8K |
| Sanders MachelleDirector · 5 transactions | +79.4% | 45.9K | 34.6K | — | 14.3K |
| Abercrombie George BDirector · 1 transaction | +23% | 36.4Kas of Jun 2024 | 6.8K | — | — |
| Frank StevenDirector · 8 transactions | — | 35.5K | 35.5K | — | — |
| Milne Jill C.Director · 5 transactions | — | 31.9K | 31.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -401.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.